Salud financiera de hoja de balance de Rhythm Pharmaceuticals
Salud financiera controles de criterios 5/6
Rhythm Pharmaceuticals tiene un patrimonio de los accionistas total de $169.8M y una deuda total de $106.1M, lo que sitúa su ratio deuda-patrimonio en 62.5%. Sus activos y pasivos totales son $332.7M y $163.0M respectivamente.
Información clave
62.5%
Ratio deuda-patrimonio
US$106.14m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$275.85m |
| Patrimonio | US$169.76m |
| Total pasivo | US$162.99m |
| Activos totales | US$332.75m |
Actualizaciones recientes sobre salud financiera
We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03
We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Is Rhythm Pharmaceuticals (NASDAQ:RYTM) In A Good Position To Deliver On Growth Plans?
Jun 04Recent updates
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22
Mar 03Rhythm Pharmaceuticals: Action Too Specific
Feb 23Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 08We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing
Jun 17Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 05Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued
Dec 15We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Oct 10Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours
Sep 14Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS
Sep 06Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts
Aug 08Rhythm Pharmaceuticals Q2 2022 Earnings Preview
Aug 01Rhythm Pharma gains as NICE recommends obesity drug
Jul 18Is Rhythm Pharmaceuticals (NASDAQ:RYTM) In A Good Position To Deliver On Growth Plans?
Jun 04Rhythm Pharmaceuticals: PDUFA Ahead, But Commercialization Concerns Remain
Jan 15Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($308.3M) de RYTM superan a sus pasivos a corto plazo ($55.2M).
Pasivo a largo plazo: Los activos a corto plazo de RYTM ($308.3M) superan a sus pasivos a largo plazo ($107.8M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: RYTM tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de RYTM ha crecido de 0% a 62.5% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: RYTM tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: Se prevé que RYTM disponga de suficiente cash runway para 11 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.